Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients

Double-Blind Placebo-Controlled Study of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients

To compare versus placebo the efficacy and safety of recombinant Bet v1, natural purified Bet v1 and birch pollen licenced extract used for subcutaneous immunotherapy.

Inclusion Criteria:

• Patients aged 18-50 with seasonal rhinoconjunctivitis for at least 2 years, and/or mild asthma range 1 and 2 GINA.
• Positive history of birch pollen allergy (clinical history, positive skin prick test, birch specific IgE, presence of birch pollen)
• Compliant patients
• Written consent.

Exclusion Criteria:

• Perennial rhinoconjunctivitis and/or asthma due to cosensitization with: animal danders, mites, alternaria cladosporium
• Uncontrolled seasonal asthma : severe asthma permanent or not range 3 and 4 of GINA.
• Patients treated with beta-blockers or under continuous oral corticosteroids.
• Pregnant women